| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | extracellular matrix structural constituent | 1.27e-05 | 188 | 16 | 4 | GO:0005201 | |
| GeneOntologyMolecularFunction | extracellular matrix structural constituent conferring tensile strength | 6.10e-04 | 46 | 16 | 2 | GO:0030020 | |
| GeneOntologyMolecularFunction | transcription corepressor activity | 7.47e-04 | 229 | 16 | 3 | GO:0003714 | |
| GeneOntologyMolecularFunction | structural molecule activity | 4.66e-03 | 891 | 16 | 4 | GO:0005198 | |
| GeneOntologyBiologicalProcess | extracellular matrix organization | 1.68e-04 | 377 | 16 | 4 | GO:0030198 | |
| GeneOntologyBiologicalProcess | extracellular structure organization | 1.70e-04 | 378 | 16 | 4 | GO:0043062 | |
| GeneOntologyBiologicalProcess | external encapsulating structure organization | 1.71e-04 | 379 | 16 | 4 | GO:0045229 | |
| GeneOntologyBiologicalProcess | regulation of anoikis | 1.81e-04 | 26 | 16 | 2 | GO:2000209 | |
| GeneOntologyBiologicalProcess | negative regulation of canonical Wnt signaling pathway | 2.13e-04 | 154 | 16 | 3 | GO:0090090 | |
| GeneOntologyBiologicalProcess | anoikis | 3.70e-04 | 37 | 16 | 2 | GO:0043276 | |
| GeneOntologyBiologicalProcess | negative regulation of Wnt signaling pathway | 4.26e-04 | 195 | 16 | 3 | GO:0030178 | |
| GeneOntologyCellularComponent | beta-catenin-TCF complex | 4.26e-05 | 13 | 16 | 2 | GO:1990907 | |
| GeneOntologyCellularComponent | collagen-containing extracellular matrix | 5.83e-04 | 530 | 16 | 4 | GO:0062023 | |
| GeneOntologyCellularComponent | extracellular matrix | 1.29e-03 | 656 | 16 | 4 | GO:0031012 | |
| GeneOntologyCellularComponent | external encapsulating structure | 1.31e-03 | 658 | 16 | 4 | GO:0030312 | |
| GeneOntologyCellularComponent | endoplasmic reticulum lumen | 1.91e-03 | 332 | 16 | 3 | GO:0005788 | |
| GeneOntologyCellularComponent | collagen trimer | 2.02e-03 | 88 | 16 | 2 | GO:0005581 | |
| MousePheno | decreased neural crest cell number | 8.33e-05 | 13 | 15 | 2 | MP:0009843 | |
| MousePheno | small trigeminal ganglion | 2.02e-04 | 20 | 15 | 2 | MP:0001093 | |
| MousePheno | abnormal adipose tissue development | 2.23e-04 | 21 | 15 | 2 | MP:0011167 | |
| MousePheno | abnormal neural crest cell morphology | 4.59e-04 | 30 | 15 | 2 | MP:0009845 | |
| MousePheno | abnormal multipotent stem cell morphology | 4.91e-04 | 31 | 15 | 2 | MP:0002400 | |
| MousePheno | abnormal neural crest morphology | 5.23e-04 | 32 | 15 | 2 | MP:0009846 | |
| MousePheno | abnormal neural crest cell migration | 5.91e-04 | 34 | 15 | 2 | MP:0002950 | |
| MousePheno | abnormal pluripotent precursor cell morphology | 9.03e-04 | 42 | 15 | 2 | MP:0002399 | |
| MousePheno | abnormal neural crest cell physiology | 9.46e-04 | 43 | 15 | 2 | MP:0012745 | |
| Domain | Groucho/TLE_N | 5.15e-09 | 5 | 16 | 3 | IPR005617 | |
| Domain | TLE_N | 5.15e-09 | 5 | 16 | 3 | PF03920 | |
| Domain | Prefoldin | 3.57e-07 | 72 | 16 | 4 | IPR009053 | |
| Domain | Groucho_enhance | 6.87e-06 | 5 | 16 | 2 | IPR009146 | |
| Domain | Collagen | 2.36e-03 | 85 | 16 | 2 | PF01391 | |
| Domain | Collagen | 2.36e-03 | 85 | 16 | 2 | IPR008160 | |
| Domain | WD40_repeat_CS | 8.48e-03 | 164 | 16 | 2 | IPR019775 | |
| Domain | WD40 | 2.02e-02 | 259 | 16 | 2 | PF00400 | |
| Domain | WD40 | 2.16e-02 | 268 | 16 | 2 | SM00320 | |
| Domain | WD40_repeat | 2.22e-02 | 272 | 16 | 2 | IPR001680 | |
| Domain | WD_REPEATS_1 | 2.31e-02 | 278 | 16 | 2 | PS00678 | |
| Domain | WD_REPEATS_2 | 2.32e-02 | 279 | 16 | 2 | PS50082 | |
| Domain | WD_REPEATS_REGION | 2.32e-02 | 279 | 16 | 2 | PS50294 | |
| Domain | WD40_repeat_dom | 2.61e-02 | 297 | 16 | 2 | IPR017986 | |
| Domain | - | 3.23e-02 | 333 | 16 | 2 | 2.130.10.10 | |
| Domain | WD40/YVTN_repeat-like_dom | 3.26e-02 | 335 | 16 | 2 | IPR015943 | |
| Pathway | REACTOME_REPRESSION_OF_WNT_TARGET_GENES | 2.82e-07 | 14 | 14 | 3 | M27402 | |
| Pathway | REACTOME_REPRESSION_OF_WNT_TARGET_GENES | 4.10e-05 | 10 | 14 | 2 | MM15156 | |
| Pathway | REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX | 7.34e-05 | 85 | 14 | 3 | M27079 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 2.94e-04 | 26 | 14 | 2 | MM14793 | |
| Pathway | REACTOME_MET_ACTIVATES_PTK2_SIGNALING | 3.92e-04 | 30 | 14 | 2 | M27772 | |
| Pathway | REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX | 4.47e-04 | 32 | 14 | 2 | MM14975 | |
| Pathway | REACTOME_MET_PROMOTES_CELL_MOTILITY | 7.35e-04 | 41 | 14 | 2 | M27778 | |
| Pathway | REACTOME_DEACTIVATION_OF_THE_BETA_CATENIN_TRANSACTIVATING_COMPLEX | 7.71e-04 | 42 | 14 | 2 | M27272 | |
| Pathway | REACTOME_COLLAGEN_CHAIN_TRIMERIZATION | 8.46e-04 | 44 | 14 | 2 | M27812 | |
| Pathway | PID_PS1_PATHWAY | 9.25e-04 | 46 | 14 | 2 | M70 | |
| Pathway | REACTOME_NOTCH1_INTRACELLULAR_DOMAIN_REGULATES_TRANSCRIPTION | 1.01e-03 | 48 | 14 | 2 | M611 | |
| Pathway | REACTOME_NON_INTEGRIN_MEMBRANE_ECM_INTERACTIONS | 1.52e-03 | 59 | 14 | 2 | M27218 | |
| Pathway | REACTOME_ASSEMBLY_OF_COLLAGEN_FIBRILS_AND_OTHER_MULTIMERIC_STRUCTURES | 1.62e-03 | 61 | 14 | 2 | M27103 | |
| Pathway | REACTOME_COLLAGEN_BIOSYNTHESIS_AND_MODIFYING_ENZYMES | 1.95e-03 | 67 | 14 | 2 | M26999 | |
| Pathway | REACTOME_SIGNALING_BY_NOTCH1 | 2.37e-03 | 74 | 14 | 2 | M616 | |
| Pathway | REACTOME_DEGRADATION_OF_BETA_CATENIN_BY_THE_DESTRUCTION_COMPLEX | 2.70e-03 | 79 | 14 | 2 | MM14754 | |
| Pathway | REACTOME_SIGNALING_BY_MET | 2.70e-03 | 79 | 14 | 2 | M27643 | |
| Pathway | PID_BETA_CATENIN_NUC_PATHWAY | 2.77e-03 | 80 | 14 | 2 | M223 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 2.92e-03 | 300 | 14 | 3 | M610 | |
| Pathway | WNT_SIGNALING | 3.41e-03 | 89 | 14 | 2 | M5493 | |
| Pathway | REACTOME_COLLAGEN_FORMATION | 3.49e-03 | 90 | 14 | 2 | M631 | |
| Pathway | REACTOME_FORMATION_OF_THE_BETA_CATENIN_TCF_TRANSACTIVATING_COMPLEX | 3.57e-03 | 91 | 14 | 2 | M27101 | |
| Pathway | REACTOME_SIGNALING_BY_WNT | 3.82e-03 | 330 | 14 | 3 | M7847 | |
| Pubmed | 3.19e-10 | 4 | 16 | 3 | 11290324 | ||
| Pubmed | 7.98e-10 | 5 | 16 | 3 | 8989517 | ||
| Pubmed | 7.98e-10 | 5 | 16 | 3 | 8365415 | ||
| Pubmed | 7.98e-10 | 5 | 16 | 3 | 10748198 | ||
| Pubmed | 1.60e-09 | 6 | 16 | 3 | 8892234 | ||
| Pubmed | 1.60e-09 | 6 | 16 | 3 | 8573724 | ||
| Pubmed | A Gro/TLE-NuRD corepressor complex facilitates Tbx20-dependent transcriptional repression. | 2.79e-09 | 7 | 16 | 3 | 24024827 | |
| Pubmed | A comparison of Notch, Hes and Grg expression during murine embryonic and post-natal development. | 4.47e-09 | 8 | 16 | 3 | 10512199 | |
| Pubmed | 4.47e-09 | 8 | 16 | 3 | 16002402 | ||
| Pubmed | Six3 and Six6 activity is modulated by members of the groucho family. | 4.47e-09 | 8 | 16 | 3 | 12441302 | |
| Pubmed | All Tcf HMG box transcription factors interact with Groucho-related co-repressors. | 1.75e-08 | 12 | 16 | 3 | 11266540 | |
| Pubmed | 6.49e-08 | 18 | 16 | 3 | 22434868 | ||
| Pubmed | Expression of Groucho/TLE proteins during pancreas development. | 1.61e-07 | 24 | 16 | 3 | 18778483 | |
| Pubmed | Differential functions of TLE1 and TLE3 depending on a specific phosphorylation site. | 1.98e-07 | 2 | 16 | 2 | 33571907 | |
| Pubmed | 1.98e-07 | 2 | 16 | 2 | 10831834 | ||
| Pubmed | Grg1 acts as a lung-specific oncogene in a transgenic mouse model. | 1.98e-07 | 2 | 16 | 2 | 16452182 | |
| Pubmed | 5.95e-07 | 3 | 16 | 2 | 8808280 | ||
| Pubmed | TLE1 is an anoikis regulator and is downregulated by Bit1 in breast cancer cells. | 5.95e-07 | 3 | 16 | 2 | 22952044 | |
| Pubmed | 5.95e-07 | 3 | 16 | 2 | 12030375 | ||
| Pubmed | Tle corepressors are differentially partitioned to instruct CD8+ T cell lineage choice and identity. | 5.95e-07 | 3 | 16 | 2 | 30045946 | |
| Pubmed | 5.95e-07 | 3 | 16 | 2 | 22354967 | ||
| Pubmed | 5.95e-07 | 3 | 16 | 2 | 10660609 | ||
| Pubmed | 6.29e-07 | 153 | 16 | 4 | 25037231 | ||
| Pubmed | 8.92e-07 | 167 | 16 | 4 | 22159717 | ||
| Pubmed | 1.08e-06 | 175 | 16 | 4 | 28071719 | ||
| Pubmed | 1.19e-06 | 4 | 16 | 2 | 20181723 | ||
| Pubmed | PRDI-BF1/Blimp-1 repression is mediated by corepressors of the Groucho family of proteins. | 1.19e-06 | 4 | 16 | 2 | 9887105 | |
| Pubmed | Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. | 1.19e-06 | 4 | 16 | 2 | 21251616 | |
| Pubmed | A role for cell cycle-regulated phosphorylation in Groucho-mediated transcriptional repression. | 1.19e-06 | 4 | 16 | 2 | 12397081 | |
| Pubmed | 1.19e-06 | 4 | 16 | 2 | 8645603 | ||
| Pubmed | 1.19e-06 | 4 | 16 | 2 | 20108349 | ||
| Pubmed | Modulation of Tcf3 repressor complex composition regulates cdx4 expression in zebrafish. | 1.19e-06 | 4 | 16 | 2 | 21666599 | |
| Pubmed | 1.98e-06 | 5 | 16 | 2 | 11238932 | ||
| Pubmed | 1.98e-06 | 5 | 16 | 2 | 1303260 | ||
| Pubmed | Separating genetic and hemodynamic defects in neuropilin 1 knockout embryos. | 2.97e-06 | 6 | 16 | 2 | 18550715 | |
| Pubmed | The role of kreisler in segmentation during hindbrain development. | 2.97e-06 | 6 | 16 | 2 | 10395784 | |
| Pubmed | 4.16e-06 | 7 | 16 | 2 | 15006356 | ||
| Pubmed | Nolz1 promotes striatal neurogenesis through the regulation of retinoic acid signaling. | 5.55e-06 | 8 | 16 | 2 | 20735826 | |
| Pubmed | Constitutive scaffolding of multiple Wnt enhanceosome components by Legless/BCL9. | 5.55e-06 | 8 | 16 | 2 | 28296634 | |
| Pubmed | Grg3/TLE3 and Grg1/TLE1 induce monohormonal pancreatic β-cells while repressing α-cell functions. | 8.91e-06 | 10 | 16 | 2 | 24487024 | |
| Pubmed | 8.91e-06 | 10 | 16 | 2 | 30571765 | ||
| Pubmed | Coexpression of Cux-1 and Notch signaling pathway components during kidney development. | 1.09e-05 | 11 | 16 | 2 | 15499562 | |
| Pubmed | Spatiotemporal mapping of vascularization and innervation in the fetal murine intestine. | 1.09e-05 | 11 | 16 | 2 | 25138596 | |
| Pubmed | 1.54e-05 | 13 | 16 | 2 | 22735158 | ||
| Pubmed | 1.80e-05 | 14 | 16 | 2 | 17202186 | ||
| Pubmed | 2.08e-05 | 15 | 16 | 2 | 9291577 | ||
| Pubmed | Coronary veins determine the pattern of sympathetic innervation in the developing heart. | 2.37e-05 | 16 | 16 | 2 | 23462468 | |
| Pubmed | 3.02e-05 | 18 | 16 | 2 | 33658226 | ||
| Pubmed | TCF and Groucho-related genes influence pituitary growth and development. | 3.02e-05 | 18 | 16 | 2 | 12907761 | |
| Pubmed | 3.02e-05 | 18 | 16 | 2 | 11731482 | ||
| Pubmed | Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics. | 3.09e-05 | 135 | 16 | 3 | 28675934 | |
| Pubmed | Transcriptional regulation of cortical neuron migration by POU domain factors. | 3.75e-05 | 20 | 16 | 2 | 11859196 | |
| Pubmed | 7.45e-05 | 28 | 16 | 2 | 17041588 | ||
| Pubmed | HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. | 9.76e-05 | 32 | 16 | 2 | 11748221 | |
| Pubmed | Gfi1b regulates the level of Wnt/β-catenin signaling in hematopoietic stem cells and megakaryocytes. | 1.10e-04 | 34 | 16 | 2 | 30894540 | |
| Pubmed | Nephric duct insertion requires EphA4/EphA7 signaling from the pericloacal mesenchyme. | 1.61e-04 | 41 | 16 | 2 | 25139858 | |
| Pubmed | Genetic variations strongly influence phenotypic outcome in the mouse retina. | 2.03e-04 | 46 | 16 | 2 | 21779340 | |
| Pubmed | 2.21e-04 | 48 | 16 | 2 | 35905011 | ||
| Pubmed | 2.35e-04 | 268 | 16 | 3 | 33640491 | ||
| Pubmed | A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. | 3.21e-04 | 298 | 16 | 3 | 32353859 | |
| Pubmed | 3.93e-04 | 64 | 16 | 2 | 22261194 | ||
| Interaction | SIX6 interactions | 6.75e-08 | 11 | 16 | 3 | int:SIX6 | |
| Interaction | RIPPLY2 interactions | 4.64e-07 | 20 | 16 | 3 | int:RIPPLY2 | |
| Interaction | SIX3 interactions | 4.64e-07 | 20 | 16 | 3 | int:SIX3 | |
| Interaction | SIX2 interactions | 1.48e-06 | 29 | 16 | 3 | int:SIX2 | |
| Interaction | ISX interactions | 1.82e-06 | 31 | 16 | 3 | int:ISX | |
| Interaction | HLX interactions | 3.14e-06 | 37 | 16 | 3 | int:HLX | |
| Interaction | GFI1B interactions | 3.39e-06 | 136 | 16 | 4 | int:GFI1B | |
| Interaction | STARD7 interactions | 3.69e-06 | 39 | 16 | 3 | int:STARD7 | |
| Interaction | SIX1 interactions | 7.40e-06 | 49 | 16 | 3 | int:SIX1 | |
| Interaction | HES6 interactions | 8.86e-06 | 52 | 16 | 3 | int:HES6 | |
| Interaction | HHEX interactions | 9.94e-06 | 54 | 16 | 3 | int:HHEX | |
| Interaction | RIPPLY1 interactions | 1.05e-05 | 55 | 16 | 3 | int:RIPPLY1 | |
| Interaction | VSX1 interactions | 1.82e-05 | 66 | 16 | 3 | int:VSX1 | |
| Interaction | MYH1 interactions | 2.79e-05 | 76 | 16 | 3 | int:MYH1 | |
| Interaction | PRDM1 interactions | 3.76e-05 | 84 | 16 | 3 | int:PRDM1 | |
| Interaction | PAX2 interactions | 3.90e-05 | 85 | 16 | 3 | int:PAX2 | |
| Interaction | GSC interactions | 4.18e-05 | 87 | 16 | 3 | int:GSC | |
| Interaction | TLE4 interactions | 4.94e-05 | 92 | 16 | 3 | int:TLE4 | |
| Interaction | FOXI1 interactions | 4.94e-05 | 92 | 16 | 3 | int:FOXI1 | |
| Interaction | VENTX interactions | 7.12e-05 | 104 | 16 | 3 | int:VENTX | |
| Interaction | EN1 interactions | 8.41e-05 | 110 | 16 | 3 | int:EN1 | |
| Interaction | PAX8 interactions | 8.64e-05 | 111 | 16 | 3 | int:PAX8 | |
| Interaction | RIPPLY3 interactions | 8.88e-05 | 112 | 16 | 3 | int:RIPPLY3 | |
| Interaction | TBR1 interactions | 9.11e-05 | 113 | 16 | 3 | int:TBR1 | |
| Interaction | TBXT interactions | 9.85e-05 | 116 | 16 | 3 | int:TBXT | |
| Interaction | RUNX1 interactions | 1.02e-04 | 324 | 16 | 4 | int:RUNX1 | |
| Interaction | PAX7 interactions | 1.20e-04 | 124 | 16 | 3 | int:PAX7 | |
| Interaction | MYL11 interactions | 1.23e-04 | 21 | 16 | 2 | int:MYL11 | |
| Interaction | TBX20 interactions | 1.23e-04 | 21 | 16 | 2 | int:TBX20 | |
| Interaction | PAX9 interactions | 1.38e-04 | 130 | 16 | 3 | int:PAX9 | |
| Interaction | TLE2 interactions | 1.58e-04 | 136 | 16 | 3 | int:TLE2 | |
| Interaction | MFAP4 interactions | 1.68e-04 | 139 | 16 | 3 | int:MFAP4 | |
| Interaction | FOXQ1 interactions | 1.76e-04 | 141 | 16 | 3 | int:FOXQ1 | |
| Interaction | SOX15 interactions | 1.76e-04 | 141 | 16 | 3 | int:SOX15 | |
| Interaction | TLX2 interactions | 1.79e-04 | 142 | 16 | 3 | int:TLX2 | |
| Interaction | NFIB interactions | 1.79e-04 | 142 | 16 | 3 | int:NFIB | |
| Interaction | GATA1 interactions | 3.10e-04 | 171 | 16 | 3 | int:GATA1 | |
| Interaction | EGR2 interactions | 3.10e-04 | 171 | 16 | 3 | int:EGR2 | |
| Interaction | TLX1 interactions | 3.32e-04 | 175 | 16 | 3 | int:TLX1 | |
| Interaction | MSX1 interactions | 3.66e-04 | 36 | 16 | 2 | int:MSX1 | |
| Interaction | GATA3 interactions | 4.03e-04 | 187 | 16 | 3 | int:GATA3 | |
| Interaction | ATN1 interactions | 4.03e-04 | 187 | 16 | 3 | int:ATN1 | |
| Interaction | NFIA interactions | 4.09e-04 | 188 | 16 | 3 | int:NFIA | |
| Interaction | HNF1B interactions | 4.22e-04 | 190 | 16 | 3 | int:HNF1B | |
| Interaction | MYOD1 interactions | 4.48e-04 | 194 | 16 | 3 | int:MYOD1 | |
| Interaction | KLF5 interactions | 4.55e-04 | 195 | 16 | 3 | int:KLF5 | |
| Interaction | FOXL1 interactions | 4.62e-04 | 196 | 16 | 3 | int:FOXL1 | |
| Interaction | GATA2 interactions | 4.83e-04 | 199 | 16 | 3 | int:GATA2 | |
| Interaction | FEV interactions | 5.12e-04 | 203 | 16 | 3 | int:FEV | |
| Interaction | PCDHB7 interactions | 5.48e-04 | 44 | 16 | 2 | int:PCDHB7 | |
| Interaction | TLE1 interactions | 5.89e-04 | 213 | 16 | 3 | int:TLE1 | |
| Interaction | SIX4 interactions | 5.99e-04 | 46 | 16 | 2 | int:SIX4 | |
| Interaction | PEX7 interactions | 6.26e-04 | 47 | 16 | 2 | int:PEX7 | |
| Interaction | ERG interactions | 6.73e-04 | 223 | 16 | 3 | int:ERG | |
| Interaction | NFIX interactions | 7.09e-04 | 227 | 16 | 3 | int:NFIX | |
| Interaction | KLF3 interactions | 7.18e-04 | 228 | 16 | 3 | int:KLF3 | |
| Interaction | FOXA3 interactions | 7.66e-04 | 52 | 16 | 2 | int:FOXA3 | |
| Interaction | NDRG1 interactions | 7.84e-04 | 235 | 16 | 3 | int:NDRG1 | |
| Interaction | TPRX2 interactions | 8.88e-04 | 56 | 16 | 2 | int:TPRX2 | |
| Interaction | HLA-DMB interactions | 9.19e-04 | 57 | 16 | 2 | int:HLA-DMB | |
| Interaction | ZNF503 interactions | 9.19e-04 | 57 | 16 | 2 | int:ZNF503 | |
| Interaction | CRX interactions | 9.81e-04 | 254 | 16 | 3 | int:CRX | |
| Interaction | GMEB2 interactions | 1.02e-03 | 60 | 16 | 2 | int:GMEB2 | |
| Interaction | PROP1 interactions | 1.02e-03 | 60 | 16 | 2 | int:PROP1 | |
| Interaction | GCM1 interactions | 1.31e-03 | 68 | 16 | 2 | int:GCM1 | |
| Interaction | TBX3 interactions | 1.34e-03 | 69 | 16 | 2 | int:TBX3 | |
| Interaction | TLX3 interactions | 1.45e-03 | 291 | 16 | 3 | int:TLX3 | |
| Interaction | C1QL4 interactions | 1.50e-03 | 73 | 16 | 2 | int:C1QL4 | |
| Interaction | TCF4 interactions | 1.60e-03 | 301 | 16 | 3 | int:TCF4 | |
| Interaction | SP7 interactions | 1.65e-03 | 304 | 16 | 3 | int:SP7 | |
| Interaction | FGL1 interactions | 1.67e-03 | 77 | 16 | 2 | int:FGL1 | |
| Interaction | HNF1A interactions | 1.80e-03 | 80 | 16 | 2 | int:HNF1A | |
| Interaction | SMG7 interactions | 1.89e-03 | 319 | 16 | 3 | int:SMG7 | |
| Interaction | NKX2-5 interactions | 1.89e-03 | 82 | 16 | 2 | int:NKX2-5 | |
| Interaction | SOX7 interactions | 1.89e-03 | 82 | 16 | 2 | int:SOX7 | |
| Interaction | QPRT interactions | 1.98e-03 | 84 | 16 | 2 | int:QPRT | |
| Interaction | IRF4 interactions | 2.03e-03 | 85 | 16 | 2 | int:IRF4 | |
| Interaction | LGALS1 interactions | 2.12e-03 | 332 | 16 | 3 | int:LGALS1 | |
| Interaction | TGFA interactions | 2.13e-03 | 87 | 16 | 2 | int:TGFA | |
| Interaction | BRIP1 interactions | 2.37e-03 | 92 | 16 | 2 | int:BRIP1 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9q21 | 2.16e-03 | 199 | 16 | 2 | chr9q21 | |
| GeneFamily | Collagens | 4.11e-04 | 46 | 12 | 2 | 490 | |
| GeneFamily | WD repeat domain containing | 1.25e-02 | 262 | 12 | 2 | 362 | |
| Coexpression | GSE22886_NAIVE_VS_MEMORY_TCELL_UP | 4.94e-06 | 194 | 16 | 4 | M4416 | |
| Coexpression | BHAT_ESR1_TARGETS_VIA_AKT1_DN | 1.60e-05 | 82 | 16 | 3 | M2235 | |
| Coexpression | NABA_CORE_MATRISOME | 1.82e-05 | 270 | 16 | 4 | MM17057 | |
| Coexpression | NABA_CORE_MATRISOME | 1.95e-05 | 275 | 16 | 4 | M5884 | |
| Coexpression | BHAT_ESR1_TARGETS_NOT_VIA_AKT1_DN | 1.98e-05 | 88 | 16 | 3 | M2232 | |
| Coexpression | WONG_ADULT_TISSUE_STEM_MODULE | 5.27e-05 | 721 | 16 | 5 | M1999 | |
| Coexpression | DODD_NASOPHARYNGEAL_CARCINOMA_UP | 1.19e-04 | 1407 | 16 | 6 | M14427 | |
| Coexpression | HE_LIM_SUN_FETAL_LUNG_C0_AIRWAY_FIBROBLAST | 1.22e-04 | 27 | 16 | 2 | M45665 | |
| Coexpression | GSE6259_CD4_TCELL_VS_CD8_TCELL_UP | 1.87e-04 | 187 | 16 | 3 | M6738 | |
| Coexpression | HAN_JNK_SINGALING_UP | 2.05e-04 | 35 | 16 | 2 | M1596 | |
| Coexpression | HALLMARK_HEDGEHOG_SIGNALING | 2.17e-04 | 36 | 16 | 2 | M5919 | |
| Coexpression | GSE12845_IGD_NEG_BLOOD_VS_DARKZONE_GC_TONSIL_BCELL_UP | 2.18e-04 | 197 | 16 | 3 | M3196 | |
| Coexpression | GSE13493_DP_VS_CD8POS_THYMOCYTE_DN | 2.28e-04 | 200 | 16 | 3 | M3315 | |
| Coexpression | HAN_JNK_SINGALING_UP | 2.69e-04 | 40 | 16 | 2 | MM1183 | |
| Coexpression | NABA_COLLAGENS | 3.11e-04 | 43 | 16 | 2 | MM17060 | |
| Coexpression | NABA_COLLAGENS | 3.26e-04 | 44 | 16 | 2 | M3005 | |
| Coexpression | ZHAN_MULTIPLE_MYELOMA_CD1_AND_CD2_DN | 5.09e-04 | 55 | 16 | 2 | M16649 | |
| ToppCell | droplet-Lung-3m-Mesenchymal-fibroblast-alveolar_fibroblast-alveolar_fibroblast_l1|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.17e-07 | 188 | 16 | 4 | b382d18fb09fb2869f3c151efa71540a7f5ed229 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.86e-07 | 194 | 16 | 4 | 8fae8061b350336299aa81f378e07deadbd55123 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 5.86e-07 | 194 | 16 | 4 | 4d7d24390fdb379f943ddcc70a63f23955e10163 | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_myofibroblast|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 6.61e-07 | 200 | 16 | 4 | 251fd2923f108cd2086961d897244b392c32ad54 | |
| ToppCell | cellseq-Mesenchymal-Myocytic-Myocytic_2-SCMF|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 6.61e-07 | 200 | 16 | 4 | b441b3771fb7d9ee7b7a104afc35e466aace2da2 | |
| ToppCell | RA-01._Fibroblast_I|RA / Chamber and Cluster_Paper | 2.81e-05 | 169 | 16 | 3 | 6373562ab3b1765060212a6a53d6543e7e942e80 | |
| ToppCell | P15-Mesenchymal-mesenchymal_fibroblast-mesenchymal_progenitor_cell|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.86e-05 | 170 | 16 | 3 | ba4ba66b624089ed50a9083176386c7941b4c7a3 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-B_(Myofibroblast)|356C / Donor, Lineage, Cell class and subclass (all cells) | 3.02e-05 | 173 | 16 | 3 | 75e26a65071b0d2f30ed0b2aa9859c488f5cf362 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|356C / Donor, Lineage, Cell class and subclass (all cells) | 3.02e-05 | 173 | 16 | 3 | 26e2e674f5d312fa8f61c11b553dc6101f063b16 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.12e-05 | 175 | 16 | 3 | 1799a7be623dc3bf53ba580a7c47d2619969d708 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L2-3_LINC00507_RPL9P17|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.17e-05 | 176 | 16 | 3 | 07abf29d681abdd6c7cc87f9eaf9377e92ce212c | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.17e-05 | 176 | 16 | 3 | 852d3da0907fe87c0ef23d75a63ce07619cf0c54 | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|390C / Donor, Lineage, Cell class and subclass (all cells) | 3.17e-05 | 176 | 16 | 3 | d2df1e435996c51213e88270af9f928e9e09a6f5 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.28e-05 | 178 | 16 | 3 | 5d6297f34e104bacefb25c4e2338b50fe13dd19a | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L2-4_RORB_GRIK1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.28e-05 | 178 | 16 | 3 | 674ee5095b98929c29e4f6bd56029a336cc4a38c | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.39e-05 | 180 | 16 | 3 | 935c091bbcd6d10b81dc4731779e5bd98205c99f | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.39e-05 | 180 | 16 | 3 | 3dd384b7f3d9582b8fec9fe05100e466e6218b76 | |
| ToppCell | facs-Lung-24m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l49|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 3.39e-05 | 180 | 16 | 3 | e9785ac2806103f725f5a5208495826354ec6e22 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.45e-05 | 181 | 16 | 3 | b116c68393d8836bac080f81a8fcbeb52e0403e7 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.57e-05 | 183 | 16 | 3 | 6d98973098c6d20c5305bce6a83a549a7d8dbfba | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3-Exc_L2-3_LINC00507_RPL9P17|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.57e-05 | 183 | 16 | 3 | 1645d4a55cd8c22d6eb47fc5c6b1e576c454f111 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.57e-05 | 183 | 16 | 3 | cc7f5a17b40e8d901885174922e5fa8877643071 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.57e-05 | 183 | 16 | 3 | 803376f5260de83c48d4f7301278d078a32b3e6e | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_D_(IT_RORB_THEMIS_LINC00507)_3|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.62e-05 | 184 | 16 | 3 | 34e316ad8e7b8667cd8ad61397281802a252744f | |
| ToppCell | PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung | 3.68e-05 | 185 | 16 | 3 | 7dcdc009c5681ee05dd18968f7e85c3403fe34af | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.68e-05 | 185 | 16 | 3 | 87c416d14ca6255bee39b16e7571553e36ee3069 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_Arw_fibro_(16)|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 3.74e-05 | 186 | 16 | 3 | 4d68ee3d32f7ef884faf402ef92b31b0eb4656f1 | |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 3.80e-05 | 187 | 16 | 3 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.05e-05 | 191 | 16 | 3 | 0fae1c2ef9f83ac7721d0a9d69455bf97eed9257 | |
| ToppCell | metastatic_Lymph_Node-Fibroblasts-Myofibroblasts|metastatic_Lymph_Node / Location, Cell class and cell subclass | 4.05e-05 | 191 | 16 | 3 | aa43b472bc8362f79ae63f09f1ca764718bbf22c | |
| ToppCell | nucseq-Mesenchymal-Myocytic-Myocytic_2-SCMF|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.11e-05 | 192 | 16 | 3 | 67e845e513e76e820f55e2f0d15eb16f2944d05c | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.11e-05 | 192 | 16 | 3 | 20ede290e01ad574afd122d72b59dbc52c595fad | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.18e-05 | 193 | 16 | 3 | b05361ffe111a38cfa26eb86e4ae62c15ac99b7b | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_osteo-stroma-osteoblast|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.24e-05 | 194 | 16 | 3 | 811b382ec3da06a6bda7360abc8b633f96b2019e | |
| ToppCell | droplet-Lung-3m-Mesenchymal-myofibroblast-myofibroblast_cell-pulmonary_interstitial_myofibroblast|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.24e-05 | 194 | 16 | 3 | 7bf6edefd13047e04665dbe34051ef3f481f85a4 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo-stroma-osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 4.24e-05 | 194 | 16 | 3 | 292ce9021678534c9eedb367b9772a9d976208a8 | |
| ToppCell | droplet-Lung-3m-Mesenchymal-myofibroblast|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.24e-05 | 194 | 16 | 3 | c992e3357f4bf3069f8d697803e5785e49a2ef0a | |
| ToppCell | droplet-Lung-3m-Mesenchymal-myofibroblast-myofibroblast_cell|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 4.24e-05 | 194 | 16 | 3 | 19e5beae2c1f8bf42cbe618e89810ce7b01a396c | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.31e-05 | 195 | 16 | 3 | 3f64e2313ec79a6d5f4013a52722d071172f6c5d | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.31e-05 | 195 | 16 | 3 | 1236dc60288c7dd91868e86e9174a2dacd3b11b3 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.31e-05 | 195 | 16 | 3 | 7a5108335353ac160b684650c5da97d6f7f4dbcf | |
| ToppCell | metastatic_Lymph_Node-Fibroblasts|metastatic_Lymph_Node / Location, Cell class and cell subclass | 4.37e-05 | 196 | 16 | 3 | 275e153347caf94edc0c50021bbab49c8696fecb | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Mesenchymal_Myocytic-myocytic_fibroblast-Myofibroblasts-Myofibroblasts_L.2.3.2.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.44e-05 | 197 | 16 | 3 | 16758f181ef07c60aee63072e1da9572c5c85414 | |
| ToppCell | COPD-Stromal-Myofibroblast|World / Disease state, Lineage and Cell class | 4.44e-05 | 197 | 16 | 3 | d51f484b4e01ac64233950d0b97fa88825ea1dbb | |
| ToppCell | 11.5-Airway-Mesenchymal-Mesenchyme_SERPINF1-high|Airway / Age, Tissue, Lineage and Cell class | 4.44e-05 | 197 | 16 | 3 | 9a053a32ff9c3a85ef9a3382453acd619cc48546 | |
| ToppCell | (5)_Fibroblasts-(5)_Fibroblast-B_(Myofibroblast)|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4) | 4.51e-05 | 198 | 16 | 3 | 196257c4420ac801ed9fbb444f11718adb7560ae | |
| ToppCell | tumor_Lung-Fibroblasts-Myofibroblasts|tumor_Lung / Location, Cell class and cell subclass | 4.51e-05 | 198 | 16 | 3 | 31f9181dab689aabe9c6182c2ef7de65ba3f0ff6 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_peribronchial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 4.51e-05 | 198 | 16 | 3 | 300d7cc56207d77168390fa1ffcbcf76767b1b80 | |
| ToppCell | Bronchial-10x5prime-Stromal-Fibroblastic-Fibro_peribronchial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 4.57e-05 | 199 | 16 | 3 | e1f1950d6f840485e263b83dc81b98910be3ae7a | |
| ToppCell | distal-mesenchymal-Myofibroblast-1|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 4.57e-05 | 199 | 16 | 3 | 79917b5225cb45b4a0ea937f79f1752346e4346e | |
| ToppCell | distal-3-mesenchymal-Myofibroblast|3 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 4.57e-05 | 199 | 16 | 3 | 1f20addc0d138fec02ed6ca4c518169c568de263 | |
| ToppCell | metastatic_Brain-Fibroblasts-FB-like_cells|metastatic_Brain / Location, Cell class and cell subclass | 4.57e-05 | 199 | 16 | 3 | 12133087eae9f0e9b6c13a71e8187117768e64ce | |
| ToppCell | Biopsy_Control_(H.)-Mesenchymal-Myofibroblasts|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 4.57e-05 | 199 | 16 | 3 | 7a227c239afdaebcac84644d9b2653a5f1a4be71 | |
| ToppCell | Bronchial-10x5prime-Stromal-Fibroblastic-Fibro_myofibroblast|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 4.57e-05 | 199 | 16 | 3 | 21335475bbfbad8a6943b8076a6c1c67f3eec5d3 | |
| ToppCell | Biopsy_Other_PF-Mesenchymal-Myofibroblasts|Biopsy_Other_PF / Sample group, Lineage and Cell type | 4.64e-05 | 200 | 16 | 3 | e504570fd7eec1524c401b1cfa9d10822d80d994 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.64e-05 | 200 | 16 | 3 | e663995fc44c340d878d66b278b7b5c2ff784301 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-B_(Myofibroblast)|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.64e-05 | 200 | 16 | 3 | 731e55070a7ff315091855bd88cda30e5a7e1a98 | |
| ToppCell | Lung_Parenchyma-Severe-Mesenchymal-Mesenchymal-Fibroblasts-3-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.64e-05 | 200 | 16 | 3 | 2cb8a39a12522a9643c6244d5e94cb4559868bb9 | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-FREM3---L2-3|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.64e-05 | 200 | 16 | 3 | 9c89e91bb630cc306a820927a36ea6fb3d13e9d7 | |
| ToppCell | distal-mesenchymal-Myofibroblast-3|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 4.64e-05 | 200 | 16 | 3 | 069c8949b33ecfdb6da32992002d4060ff6082bc | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.64e-05 | 200 | 16 | 3 | 0f23e72649a274043bf23e0952a9b5707c516acf | |
| ToppCell | Parenchyma_COVID-19-Stromal-TX-Fibroblasts-3|Parenchyma_COVID-19 / Sample group, Lineage and Cell type | 4.64e-05 | 200 | 16 | 3 | 8cc5057b0e5ae9b72ea40d2ffbc52b79bf87ccef | |
| ToppCell | Bronchus_Control_(B.)-Stromal-TX-Fibroblasts-1|Bronchus_Control_(B.) / Sample group, Lineage and Cell type | 4.64e-05 | 200 | 16 | 3 | 16a3685c41194a0a4a772e4eee372160263480e0 | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-FREM3--|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.64e-05 | 200 | 16 | 3 | 96b1d2e70fbbba744fd4356a70efcf356aca9abc | |
| ToppCell | Parenchymal-10x3prime_v2-Stromal-Fibroblastic-Fibro_peribronchial|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 4.64e-05 | 200 | 16 | 3 | efdf7066b7dd43e35dbc0d2719b75f250cf54af2 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|367C / Donor, Lineage, Cell class and subclass (all cells) | 4.64e-05 | 200 | 16 | 3 | 082e718c1da3f4fdd33a001d15ad3ddb2be985c7 | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-3|Control / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.64e-05 | 200 | 16 | 3 | 07641f476cb1a131c2a50258b88cc13bb38c8379 | |
| ToppCell | Parenchyma_Control_(B.)-Stromal-TX-Fibroblasts-3|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 4.64e-05 | 200 | 16 | 3 | 343fa6ba1f52d816d2e41466f674ff8360aecd81 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_myofibroblast|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 4.64e-05 | 200 | 16 | 3 | 54806080b5e97859ee6a4a9b4f19e22021c218f5 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.64e-05 | 200 | 16 | 3 | fb53be20392a8309a7393774c774a1b1aec6e676 | |
| ToppCell | (5)_Fibroblast-B_(Myofibroblast)|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 4.64e-05 | 200 | 16 | 3 | 9bbaa666d0f3b4782c1b4b95e0fa5fc1467842d8 | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-FREM3|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.64e-05 | 200 | 16 | 3 | ad6f1d4d7f5d7bab2ba2e4fff58c535290065c0e | |
| ToppCell | Lung_Parenchyma-Control-Mesenchymal-Mesenchymal-Fibroblasts-3-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.64e-05 | 200 | 16 | 3 | d0c00cdd52c2e001aec9b935f4e981ba77d0386a | |
| ToppCell | Neuronal-Excitatory-eA(LAMP5_LINC00507)-FREM3-|Neuronal / cells hierarchy compared to all cells using T-Statistic | 4.64e-05 | 200 | 16 | 3 | 8821574d17b55dfea3ca0204e6b4c0ca6b19588a | |
| ToppCell | Biopsy_IPF-Mesenchymal-Myofibroblasts|Biopsy_IPF / Sample group, Lineage and Cell type | 4.64e-05 | 200 | 16 | 3 | c2c6f687c49ba790174b27c7b8b084af30b34c86 | |
| ToppCell | distal-mesenchymal-Myofibroblast|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 4.64e-05 | 200 | 16 | 3 | 61854a459385cd9295be37157a8f81a2c227dff3 | |
| ToppCell | Hippocampus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Nxph3-Excitatory_Neuron.Slc17a7-Slc17a6.Nxph3-Nts_(Subiculum)-|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.33e-04 | 76 | 16 | 2 | 355a6793e2828728da62357bd2250735b0fd76b1 | |
| ToppCell | Hippocampus-Neuronal-Excitatory-eN2(Slc17a7_Slc17a6)-Nxph3-Excitatory_Neuron.Slc17a7-Slc17a6.Nxph3-Nts_(Subiculum)|Hippocampus / BrainAtlas - Mouse McCarroll V32 | 3.33e-04 | 76 | 16 | 2 | 2c304b41c04a567874126df25b15d8ee2ad2b6d9 | |
| ToppCell | lymphoid-T_cell-pro-T_cell|lymphoid / Lineage, cell class and subclass | 5.52e-04 | 98 | 16 | 2 | 4da11182885d5f2673e85bd9c5717939b0268427 | |
| ToppCell | frontal_cortex-Neuronal-GABAergic_neuron-Sst-Sst_Rxfp1_Prdm8|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 8.40e-04 | 121 | 16 | 2 | 2ae870f822488799cd0ad85e7f72af64e33a867f | |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn_(Dcn)-|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 9.10e-04 | 126 | 16 | 2 | f1f24b06d301c266226d1a59dd28585f5ac68f29 | |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_TIP-Dcn_1|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 9.10e-04 | 126 | 16 | 2 | fe6900eb37e4f09465a1276586c73dd38545fa2a | |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 9.10e-04 | 126 | 16 | 2 | 1ac4cc747e466bc79e33b97608b19ad29a7a6a41 | |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_TIP-Dcn_1-Dcn_1_1-Endothelial_Tip.Dcn_(Dcn)|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 9.10e-04 | 126 | 16 | 2 | 2de551d7a8765afec1da8852727c79fec90f45f8 | |
| ToppCell | Entopeduncular-Endothelial-ENDOTHELIAL_TIP|Entopeduncular / BrainAtlas - Mouse McCarroll V32 | 9.10e-04 | 126 | 16 | 2 | 3d507f829882d043f633db2612b76936e2042445 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Undifferentiated_Pleomorphic_Sarcoma-7|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 9.24e-04 | 127 | 16 | 2 | c4809d8502f460370f824719d69b13b400a2b202 | |
| ToppCell | LPS-antiTNF-Epithelial_alveolar-Mes-Like-Differentiating_AT1|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.39e-04 | 128 | 16 | 2 | 2cf0384240a4a663869cf6b27d954236f6214a9a | |
| ToppCell | Bronchial_Biopsy-Mesenchymal-Fibroblasts|Mesenchymal / Tissue, Lineage and Cell class of Lung Cells from 10X | 9.53e-04 | 129 | 16 | 2 | 13cd10ffdd8f1ef7721884e9efd2cf25f170f414 | |
| ToppCell | facs-Heart-Unknown-3m-Endothelial-endothelial_cell_of_coronary_artery|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.14e-03 | 141 | 16 | 2 | 4aa4b3476dc5abefbd348353cfe711cd5fe3d52f | |
| ToppCell | facs-Heart-Unknown-3m-Endothelial-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.14e-03 | 141 | 16 | 2 | e40c6f1b7fbaa46b3eaa55f1b37ef360b04370a8 | |
| ToppCell | facs-Heart-Unknown-3m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.15e-03 | 142 | 16 | 2 | 759fbbd15b4fb313bd6269b7f087edafebd530ef | |
| ToppCell | 343B-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_4|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells) | 1.17e-03 | 143 | 16 | 2 | ce045ec7c311a1797ae562bec114f9e90604d063 | |
| ToppCell | Control-Plasmablast|World / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 1.20e-03 | 145 | 16 | 2 | fe68582f5a15b9714cb84fa32ac880e13cb69895 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD8_c01-LEF1|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.20e-03 | 145 | 16 | 2 | 42dd36c1bc2c43cfea7196e89f901e4ea2a403c7 | |
| ToppCell | IIH-CD8-proli_CD4|IIH / Condition, Cell_class and T cell subcluster | 1.22e-03 | 146 | 16 | 2 | 7fa6e35def3f7cffbee1e1c2f10b523bab678e14 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_E|367C / Donor, Lineage, Cell class and subclass (all cells) | 1.27e-03 | 149 | 16 | 2 | f18bddc84b064f3d57a1281d5172c404d87f25da | |
| ToppCell | normal_Lung-Myeloid_cells-Undetermined|normal_Lung / Location, Cell class and cell subclass | 1.30e-03 | 151 | 16 | 2 | 23b6cf9a36ad0e937f69c75921bddd305a9a526c | |
| ToppCell | severe_COVID-19-MAIT|World / disease group, cell group and cell class (v2) | 1.35e-03 | 154 | 16 | 2 | 65ec7f7ef05c589903c4c9fe3849478c325fdc61 | |
| ToppCell | 356C-Myeloid-Macrophage-FABP4+_Macrophage_3|356C / Donor, Lineage, Cell class and subclass (all cells) | 1.37e-03 | 155 | 16 | 2 | e1a20e88b9c0eaf7ca7004acc0eda096d1588563 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-chondrocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.41e-03 | 157 | 16 | 2 | f147e24f2ece82e1c54750868954d09b3c461804 | |
| Drug | AC1L1C2F | 8.98e-07 | 110 | 16 | 4 | CID000001711 | |
| Drug | NSC49633 | 6.53e-06 | 53 | 16 | 3 | CID000023340 | |
| Drug | Syrosingopine [84-36-6]; Down 200; 6uM; MCF7; HT_HG-U133A | 7.91e-06 | 190 | 16 | 4 | 6213_DN | |
| Drug | Triprolidine hydrochloride [550-70-9]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 8.41e-06 | 193 | 16 | 4 | 7008_DN | |
| Drug | Diloxanide furoate [3736-81-0]; Up 200; 12.2uM; HL60; HT_HG-U133A | 9.12e-06 | 197 | 16 | 4 | 3062_UP | |
| Drug | Nialamide [51-12-7]; Up 200; 13.4uM; PC3; HT_HG-U133A | 9.30e-06 | 198 | 16 | 4 | 4525_UP | |
| Drug | hyaluronan | 2.84e-05 | 263 | 16 | 4 | CID000024759 | |
| Drug | ALT-711 | 9.65e-05 | 21 | 16 | 2 | CID000216304 | |
| Drug | DMSe | 1.01e-04 | 132 | 16 | 3 | CID000020796 | |
| Drug | khellin | 2.17e-04 | 171 | 16 | 3 | CID000003828 | |
| Drug | Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 2.87e-04 | 188 | 16 | 3 | 6451_DN | |
| Drug | GK-101 | 2.88e-04 | 36 | 16 | 2 | CID000161853 | |
| Drug | PF-00562151-00 [351320-12-2]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.96e-04 | 190 | 16 | 3 | 6912_DN | |
| Drug | Pipenzolate bromide [125-51-9]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 3.05e-04 | 192 | 16 | 3 | 3460_UP | |
| Drug | Hydrocortisone base [50-23-7]; Up 200; 11uM; PC3; HT_HG-U133A | 3.05e-04 | 192 | 16 | 3 | 6684_UP | |
| Drug | Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 3.14e-04 | 194 | 16 | 3 | 3280_DN | |
| Drug | Oxymetazoline hydrochloride [2315-02-8]; Up 200; 13.4uM; PC3; HT_HG-U133A | 3.14e-04 | 194 | 16 | 3 | 2114_UP | |
| Drug | chlorpromazine hydrochloride; Up 200; 1uM; HL60; HT_HG-U133A | 3.19e-04 | 195 | 16 | 3 | 6176_UP | |
| Drug | Famprofazone [22881-35-2]; Up 200; 10.6uM; PC3; HT_HG-U133A | 3.19e-04 | 195 | 16 | 3 | 4309_UP | |
| Drug | Sulfaguanidine [57-67-0]; Up 200; 18.6uM; MCF7; HT_HG-U133A | 3.24e-04 | 196 | 16 | 3 | 1495_UP | |
| Drug | Metampicillin sodium salt [6489-61-8]; Up 200; 10.4uM; HL60; HG-U133A | 3.24e-04 | 196 | 16 | 3 | 1440_UP | |
| Drug | Parbendazole [14255-87-9]; Up 200; 16.2uM; PC3; HT_HG-U133A | 3.24e-04 | 196 | 16 | 3 | 4535_UP | |
| Drug | Apramycin [37321-09-8]; Down 200; 7.4uM; HL60; HT_HG-U133A | 3.24e-04 | 196 | 16 | 3 | 2914_DN | |
| Drug | Paclitaxel [33069-62-4]; Up 200; 4.6uM; MCF7; HT_HG-U133A | 3.24e-04 | 196 | 16 | 3 | 5320_UP | |
| Drug | Pyrazinamide [ 98-96-4]; Up 200; 32.4uM; HL60; HT_HG-U133A | 3.24e-04 | 196 | 16 | 3 | 2478_UP | |
| Drug | Zardaverine [101975-10-4]; Down 200; 15uM; MCF7; HT_HG-U133A | 3.29e-04 | 197 | 16 | 3 | 7347_DN | |
| Drug | Tiletamine hydrochloride; Up 200; 15.4uM; MCF7; HT_HG-U133A | 3.29e-04 | 197 | 16 | 3 | 6516_UP | |
| Drug | Bendroflumethiazide [73-48-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A | 3.29e-04 | 197 | 16 | 3 | 3415_DN | |
| Drug | Flunixin meglumine [42461-84-7]; Up 200; 8.2uM; HL60; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 2552_UP | |
| Drug | Pargyline hydrochloride [306-07-0]; Down 200; 20.4uM; MCF7; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 7016_DN | |
| Drug | Cortisone [53-06-5]; Up 200; 11uM; HL60; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 2385_UP | |
| Drug | Metformin hydrochloride [1115-70-4]; Up 200; 24.2uM; MCF7; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 1694_UP | |
| Drug | Diphenylpyraline hydrochloride [132-18-3]; Up 200; 12.6uM; MCF7; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 4765_UP | |
| Drug | (R)-(+)-Atenolol [56715-13-0]; Up 200; 15uM; HL60; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 2496_UP | |
| Drug | radicicol, diheterospora chlamydosporia; Up 200; 0.1uM; HL60; HT_HG-U133A | 3.34e-04 | 198 | 16 | 3 | 6178_UP | |
| Drug | Proglumide [6620-60-6]; Up 200; 12uM; HL60; HT_HG-U133A | 3.39e-04 | 199 | 16 | 3 | 2363_UP | |
| Drug | Cyproheptadine hydrochloride [969-33-5]; Down 200; 12.4uM; PC3; HT_HG-U133A | 3.39e-04 | 199 | 16 | 3 | 6740_DN | |
| Drug | Meptazinol hydrochloride [59263-76-2]; Up 200; 14.8uM; PC3; HT_HG-U133A | 3.39e-04 | 199 | 16 | 3 | 4188_UP | |
| Drug | Strophanthidin [66-28-4]; Down 200; 9.8uM; MCF7; HT_HG-U133A | 3.44e-04 | 200 | 16 | 3 | 7182_DN | |
| Drug | Clorgyline hydrochloride [17780-75-5]; Up 200; 13uM; PC3; HT_HG-U133A | 3.44e-04 | 200 | 16 | 3 | 6659_UP | |
| Drug | Enilconazole [35554-44-0]; Up 200; 13.4uM; MCF7; HT_HG-U133A | 3.44e-04 | 200 | 16 | 3 | 6518_UP | |
| Drug | p-Nitrophenyl alpha-D-xyloside | 3.74e-04 | 41 | 16 | 2 | CID000082482 | |
| Drug | fluvalinate | 4.31e-04 | 44 | 16 | 2 | CID000050516 | |
| Drug | Madecassol | 4.71e-04 | 46 | 16 | 2 | CID000108062 | |
| Drug | TMTU | 4.71e-04 | 46 | 16 | 2 | CID000017725 | |
| Disease | severe acute respiratory syndrome, COVID-19 | 1.37e-03 | 447 | 15 | 3 | EFO_0000694, MONDO_0100096 | |
| Disease | spine bone mineral density | 1.64e-03 | 119 | 15 | 2 | EFO_0007701 | |
| Disease | age at onset, Myopia | 2.58e-03 | 150 | 15 | 2 | EFO_0004847, HP_0000545 | |
| Disease | refractive error, age at onset, Myopia | 4.23e-03 | 193 | 15 | 2 | EFO_0004847, HP_0000545, MONDO_0004892 | |
| Disease | amino acid measurement | 4.47e-03 | 678 | 15 | 3 | EFO_0005134 | |
| Disease | Autistic Disorder | 7.59e-03 | 261 | 15 | 2 | C0004352 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| YTVNDLSMMKYYYEC | 386 | Q8N4J0 | |
| EMDMISYNYDYYIRG | 156 | Q07507 | |
| LDMMQIYDGKKYYIY | 156 | Q9BZ81 | |
| KYYLEGVSNEMYTEY | 591 | Q12791 | |
| DSKTVGQYEYYKVYM | 66 | P52799 | |
| GQYEYYKVYMVDKDQ | 71 | P52799 | |
| RMEIREKYYYAVYDM | 251 | P07942 | |
| GLMEMAYNEYINEYY | 1956 | Q9BZC7 | |
| TNYYVYYDTDMDQAM | 406 | Q6NUM9 | |
| VMYTYDEYTKGYLDQ | 621 | Q03692 | |
| DYYYYEDLNTMLEME | 471 | Q17RW2 | |
| YVMYYEMSYGLNIEM | 61 | Q08117 | |
| YVMYYEMSYGLNIEM | 61 | Q04724 | |
| MVQMGEEYYYAKDYT | 456 | Q7Z392 | |
| YVMYYEMSYGLNIEM | 61 | Q04726 | |
| LVRPSMYDYYDMDNY | 721 | Q9H9Y6 | |
| MYDYYDMDNYPIGTN | 726 | Q9H9Y6 | |
| MYKMEYSYLNSSAYE | 1 | Q99453 |